Global Rotavirus Vaccines Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rotavirus Vaccines Market Research Report 2024
Rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. The vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of severe diarrhea in the developed world. The vaccines decrease the risk of death among young children due to diarrhea. Immunizing babies decreases rates of disease among older people and those who have not been immunized.
The World Health Organization (WHO) recommends that rotavirus vaccine be included in national routine vaccinations programs, especially in areas where the disease is common. This should be done along with promoting breastfeeding, handwashing, clean water and good sanitation. It is given by mouth and requires two or three doses. It should be given starting around six weeks of age.
The vaccines are safe. This includes their use in people with HIV/AIDS. An earlier vaccine that is no longer used was linked to intussusception, but the current versions are not clearly linked. Due to a potential risk they are not recommended in babies who have had intussusception. The vaccines are made from weakened rotavirus.
The vaccine first became available in the United States in 2006. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between US$6.96 and $20.66 per dose as of 2014.In the United States it is more than US$200. As of 2013 there are two types of vaccine available globally, Rotarix and RotaTeq. Others are used in some countries.
According to Mr Accuracy reports’s new survey, global Rotavirus Vaccines market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rotavirus Vaccines market research.
Key manufacturers engaged in the Rotavirus Vaccines industry include Bharat Biotech, Merck & Co., Inc, GlaxoSmithKline plc, Lanzhou Institute of Biological and Bharat Biotech International Limited, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Rotavirus Vaccines were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Rotavirus Vaccines market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rotavirus Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Bharat Biotech
Merck & Co., Inc
GlaxoSmithKline plc
Lanzhou Institute of Biological
Bharat Biotech International Limited
Segment by Type
Rotarix
RotaTeq
Rotavac
Rotavin-M1
Lanzhou lamb
Others
Adult
Pediatric
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Rotavirus Vaccines report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
The World Health Organization (WHO) recommends that rotavirus vaccine be included in national routine vaccinations programs, especially in areas where the disease is common. This should be done along with promoting breastfeeding, handwashing, clean water and good sanitation. It is given by mouth and requires two or three doses. It should be given starting around six weeks of age.
The vaccines are safe. This includes their use in people with HIV/AIDS. An earlier vaccine that is no longer used was linked to intussusception, but the current versions are not clearly linked. Due to a potential risk they are not recommended in babies who have had intussusception. The vaccines are made from weakened rotavirus.
The vaccine first became available in the United States in 2006. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between US$6.96 and $20.66 per dose as of 2014.In the United States it is more than US$200. As of 2013 there are two types of vaccine available globally, Rotarix and RotaTeq. Others are used in some countries.
According to Mr Accuracy reports’s new survey, global Rotavirus Vaccines market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rotavirus Vaccines market research.
Key manufacturers engaged in the Rotavirus Vaccines industry include Bharat Biotech, Merck & Co., Inc, GlaxoSmithKline plc, Lanzhou Institute of Biological and Bharat Biotech International Limited, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Rotavirus Vaccines were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Rotavirus Vaccines market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rotavirus Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bharat Biotech
Merck & Co., Inc
GlaxoSmithKline plc
Lanzhou Institute of Biological
Bharat Biotech International Limited
Segment by Type
Rotarix
RotaTeq
Rotavac
Rotavin-M1
Lanzhou lamb
Others
Segment by Application
Adult
Pediatric
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Rotavirus Vaccines report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices